Financial Performance - Total revenue for Q3 2025 reached ¥741,287,436.95, an increase of 3.48% year-over-year[5] - Net profit attributable to shareholders was ¥1,681,675.27, representing a significant increase of 106.13% compared to the same period last year[5] - The net profit after deducting non-recurring gains and losses was ¥3,888,911.87, up 114.40% year-over-year[5] - Basic earnings per share for Q3 2025 was ¥0.01, reflecting a growth of 105.56% compared to the previous year[5] - Total operating revenue for the period reached ¥2,200,549,440.39, an increase from ¥2,136,699,863.80 in the previous period, representing a growth of approximately 3.9%[18] - Net profit for the period was ¥21,588,547.06, slightly down from ¥22,845,948.88, reflecting a decrease of approximately 5.5%[19] - The total comprehensive income for the period was CNY 21,588,547.06, compared to CNY 22,845,948.88 in the previous period[20] - Basic and diluted earnings per share remained stable at CNY 0.11 for both periods[20] Assets and Liabilities - Total assets as of September 30, 2025, amounted to ¥4,606,956,437.82, a slight increase of 0.19% from the end of the previous year[5] - Total liabilities decreased to ¥2,465,547,256.68 from ¥2,476,861,122.42, a reduction of approximately 0.5%[17] - Total assets increased to ¥4,606,956,437.82 from ¥4,598,026,724.34, indicating a growth of about 0.2%[17] - Long-term equity investments increased to ¥207,109,185.61 from ¥170,089,374.50, reflecting a growth of about 21.8%[16] Cash Flow - Cash flow from operating activities for the year-to-date was ¥414,125,450.17, showing a slight decrease of 0.08% compared to the previous year[5] - The net cash flow from operating activities was CNY 414,125,450.17, slightly down from CNY 414,469,212.80 in the previous period[22] - Cash inflow from operating activities totaled CNY 2,236,276,463.31, an increase from CNY 2,184,953,764.81 year-over-year[22] - Net cash flow from investing activities decreased by 51.03% to -300,349,269.24 RMB, as all hospitals under construction have opened, leading to a significant reduction in fixed investments[10] - The net cash flow from investing activities was -CNY 300,349,269.24, improving from -CNY 613,278,600.03 in the previous period[23] - Cash and cash equivalents at the end of the period were CNY 376,140,370.20, down from CNY 479,822,198.29 at the end of the previous period[23] - The total cash outflow from financing activities was CNY 298,538,469.65, compared to CNY 606,582,850.80 in the previous period[23] Shareholder Information - The total number of common shareholders at the end of the reporting period was 10,438, with no preferred shareholders having restored voting rights[10] - Chengdu Puri Century Investment Co., Ltd. holds 35.91% of shares, amounting to 53,729,585 shares, with 24,941,200 shares pledged[10] - Xu Xuyang, a natural person, holds 6.75% of shares, totaling 10,100,000 shares, with 7,575,000 shares under lock-up[10] - The top ten shareholders collectively hold significant stakes, with the largest shareholder holding nearly 36% of the total shares[11] - The total number of unrestricted shares held by the top ten unrestricted shareholders is 78,829,585 shares[13] - The company has a high concentration of ownership, with the top shareholder being the actual controller of several management partnerships[11] - There are no preferred shareholders or changes in restricted shares reported for the current period[12] Operational Costs and Expenses - Total operating costs amounted to ¥2,105,665,391.88, up from ¥2,058,379,113.42, indicating an increase of about 2.3%[18] - Research and development expenses increased by 65.77% to ¥8,086,821.35, primarily due to higher IT R&D costs[9] - The company experienced a 295.01% decline in investment income, resulting in a loss of ¥2,523,117.09, mainly due to increased losses from joint ventures[9] - The company's cash and cash equivalents decreased to ¥376,140,370.20 from ¥481,067,596.27, a decline of about 21.8%[15] - Accounts receivable increased to ¥104,567,385.64 from ¥101,080,594.08, showing a growth of approximately 4.9%[15] - Inventory rose to ¥186,303,726.69 from ¥148,312,611.64, marking an increase of about 25.6%[16] - Total current assets slightly increased to ¥873,122,319.94 from ¥869,259,065.91, a growth of approximately 0.3%[16]
普瑞眼科(301239) - 2025 Q3 - 季度财报